Credit: Science Photo Although it is the most common endocrine cause of secondary hypertension, primary aldosteronism remains underdiagnosed. With emerging research focused on potential new therapies ...

What if there were a straightforward and relatively inexpensive way to lower the incidence of heart failure (HF), renal disease, stroke, and cognitive impairment? Cardiologist Bertram Pitt, MD, said ...

A speedy new scan could improve how millions of people with high blood pressure are treated, suggests a new study led by UCL (University College London) researchers. About a quarter of people with ...

It’s rare for a dictionary to claim that a word has no definition. But that’s what Dictionary.com said about its recently announced word of the year: “67,” pronounced “six-seven,” the slang term that ...

I'm the princess and the pea when it comes to sofas. My husband will attest that I've had complaints about all four couches we've owned since getting married six years ago. Our first sofa felt flimsy, ...

A highly selective aldosterone synthase inhibitor, lorundrostat, showed promise for blood pressure reduction in a double-blind randomized phase IIb trial. Participants with uncontrolled and otherwise ...

In this Q&A, Mineralys CEO Jon Congleton discusses how targeting aldosterone could reshape hypertension treatment. Aldosterone synthase inhibitors (ASIs) are drawing a lot of attention. What first ...

Aldosterone dysregulation plays an important pathogenic role in hard-to-control hypertension. In several studies, baxdrostat, an aldosterone synthase inhibitor, reduced the seated systolic blood ...

In Define Ventures’ AI investing thesis, released Thursday, the health tech venture fund outlines a vision of artificial intelligence readiness to reengineer healthcare. It’s investing in founders ...

Current treatment options for primary aldosteronism are limited to surgery or mineralocorticoid receptor antagonists when surgery isn't an option. In a phase IIa trial, baxdrostat resolved or reduced ...

The data from the Launch-HTN trial, announced at the 34th European Meeting on Hypertension and Cardiovascular Protection, show that lorundrostat, an aldosterone synthase inhibitor, is a safe and ...

Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...